OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ITOR.PK56

Redox International Group Corp

Healthcare Facilities & ServicesVerified

Redox International Group Corp has a highly leveraged capital structure, with total liabilities of $30,480 million and total equity of -$25,010 million, resulting in a negative debt-to-equity ratio of -0.36. The company's liquidity position is weak, as evidenced by a current ratio of 0.06, indicating that it has only $0.06 in current assets for every $1 of current liabilities. The operating cash flow of -$16,780 million further highlights the company's cash flow challenges, which could limit its ability to meet short-term obligations. Profitability metrics are severely negative, with a net income of -$3,620 million and an operating income of -$3,620 million, indicating that the company is not generating positive earnings from its core operations. The return on equity of 14.47% is misleading due to the negative equity base, and the return on assets of -6.61% suggests that the company is not effectively utilizing its assets to generate profit. These figures are well below the industry median for profitability metrics, which typically show positive returns for companies in the healthcare services and equipment sector. The company's revenue of $1,600 million is relatively small compared to its liabilities and equity, and there is no detailed breakdown of revenue by segment or geography in the provided data. This lack of segmentation makes it difficult to assess the company's exposure to different markets or product lines. However, the negative equity and high debt levels suggest that the company may be heavily reliant on a few key markets or products, which could increase its vulnerability to market fluctuations. The company's growth trajectory is uncertain, as there is no clear indication of revenue growth in the provided data. The negative operating cash flow and net income suggest that the company is not in a position to sustain growth without external financing. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the key flag of negative net cash after subtracting total debt highlights the company's financial instability. The dilution potential is low, but the company may need to issue additional shares to raise capital, which could dilute existing shareholders' equity. Recent events and filings have not been provided in the input data, so it is not possible to assess the company's recent performance or strategic initiatives. However, the financial snapshot suggests that the company is facing significant financial challenges that may require restructuring or additional financing to address. The company's risk profile is dominated by liquidity and solvency concerns, with a negative equity position and high debt levels. The risk assessment indicates a medium liquidity risk, which is consistent with the company's weak current ratio and negative operating cash flow. The credit risk is also high due to the company's inability to generate positive cash flow and its reliance on debt financing. The dilution risk is currently low, but the company may need to issue additional shares to raise capital, which could increase the dilution risk in the future.

30-day price · ITOR.PK(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyRedox International Group Corp
TickerITOR.PK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Redox International Group Corp is a biotechnology company that operates within the healthcare facilities and services industry, primarily generating revenue through its healthcare services and equipment offerings.

Classification. Redox International Group Corp is classified under the Healthcare economic sector, Healthcare Services & Equipment business sector, and Healthcare Facilities & Services industry, with a classification confidence of 0.92.

Redox International Group Corp has a highly leveraged capital structure, with total liabilities of $30,480 million and total equity of -$25,010 million, resulting in a negative debt-to-equity ratio of -0.36. The company's liquidity position is weak, as evidenced by a current ratio of 0.06, indicating that it has only $0.06 in current assets for every $1 of current liabilities. The operating cash flow of -$16,780 million further highlights the company's cash flow challenges, which could limit its ability to meet short-term obligations. Profitability metrics are severely negative, with a net income of -$3,620 million and an operating income of -$3,620 million, indicating that the company is not generating positive earnings from its core operations. The return on equity of 14.47% is misleading due to the negative equity base, and the return on assets of -6.61% suggests that the company is not effectively utilizing its assets to generate profit. These figures are well below the industry median for profitability metrics, which typically show positive returns for companies in the healthcare services and equipment sector. The company's revenue of $1,600 million is relatively small compared to its liabilities and equity, and there is no detailed breakdown of revenue by segment or geography in the provided data. This lack of segmentation makes it difficult to assess the company's exposure to different markets or product lines. However, the negative equity and high debt levels suggest that the company may be heavily reliant on a few key markets or products, which could increase its vulnerability to market fluctuations. The company's growth trajectory is uncertain, as there is no clear indication of revenue growth in the provided data. The negative operating cash flow and net income suggest that the company is not in a position to sustain growth without external financing. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the key flag of negative net cash after subtracting total debt highlights the company's financial instability. The dilution potential is low, but the company may need to issue additional shares to raise capital, which could dilute existing shareholders' equity. Recent events and filings have not been provided in the input data, so it is not possible to assess the company's recent performance or strategic initiatives. However, the financial snapshot suggests that the company is facing significant financial challenges that may require restructuring or additional financing to address. The company's risk profile is dominated by liquidity and solvency concerns, with a negative equity position and high debt levels. The risk assessment indicates a medium liquidity risk, which is consistent with the company's weak current ratio and negative operating cash flow. The credit risk is also high due to the company's inability to generate positive cash flow and its reliance on debt financing. The dilution risk is currently low, but the company may need to issue additional shares to raise capital, which could increase the dilution risk in the future.
Key takeaways
  • Redox International Group Corp has a highly leveraged capital structure with a negative debt-to-equity ratio of -0.36.
  • The company is not generating positive earnings, with a net income and operating income of -$3,620 million.
  • The company's liquidity position is weak, as indicated by a current ratio of 0.06 and a negative operating cash flow of -$16,780 million.
  • The company's return on equity is 14.47%, but this is misleading due to the negative equity base.
  • The company's financial stability is at risk due to its high debt levels and negative equity position.
  • The company may need to issue additional shares to raise capital, which could dilute existing shareholders' equity.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$1.6k
Gross profit
Operating income-$3.6k
Net income-$3.6k
R&D
SG&A
D&A
SBC
Operating cash flow-$16.8k
CapEx
Free cash flow
Total assets$5.5k
Total liabilities$30.5k
Total equity-$25.0k
Cash & equivalents
Long-term debt$9.0k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4
FY-3-$1.8k-$1.8k
FY-2-$22.7k-$22.7k
FY-1$2.1k-$25.4k-$25.4k
FY0$4.8k-$27.2k-$27.2k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4
FY-3$9.0k-$1.6k
FY-2$22.2k$440.00
FY-1$5.5k-$25.0k
FY0$1.9k-$52.2k
PeriodOCFCapExFCFSBC
FY-4
FY-3-$1.2k
FY-2-$14.0k
FY-1-$16.8k
FY0-$18.6k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$1.6k-$3.6k-$3.6k
FQ-6$1.4k-$9.9k-$9.9k
FQ-5$750.00-$3.6k-$3.6k
FQ-4$2.0k-$2.4k-$2.4k
FQ-3$750.00-$11.4k-$11.4k
FQ-2$0.00-$920.00-$1.9k
FQ-1$0.00-$12.9k-$12.9k
FQ0$0.00-$14.3k-$14.3k-$14.3k
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$5.5k-$25.0k
FQ-6$5.7k-$34.9k
FQ-5$4.0k-$38.5k
FQ-4$3.6k-$40.9k
FQ-3$1.9k-$52.2k
FQ-2$0.00$0.00
FQ-1$0.00-$12.9k
FQ0$48.9k-$27.2k
PeriodOCFCapExFCFSBC
FQ-7-$16.8k
FQ-6-$7.7k
FQ-5-$9.1k
FQ-4-$9.4k
FQ-3-$18.6k
FQ-2-$920.00
FQ-1-$3.5k
FQ0-$12.4k$0.00-$14.3k
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$25.0k
Net cash-$9.0k
Current ratio0.1
Debt/Equity-0.4
ROA-66.1%
ROE14.5%
Cash conversion4.6%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricITOR.PKActivity
Op margin-226.3%5.6% medp25 -4.2% · p75 12.6%bottom quartile
Net margin-226.3%2.8% medp25 -3.4% · p75 8.8%bottom quartile
Gross margin36.5% medp25 23.7% · p75 65.2%
CapEx / revenue-4.9% medp25 -11.5% · p75 -2.0%
Debt / equity-36.0%69.3% medp25 7.9% · p75 120.9%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 00:22 UTC#0e29d2d3
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 06:14 UTCJob: 5e52424c